UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

653P A phase I dose escalation study of EBC-129, a first-in class, anti N-glycosylated CEACAM5 & CEACAM6 antibody-drug conjugate (ADC) in patients with solid tumors

Annals of oncology, 2024-09, Vol.35, p.S516-S516

2024

Volltextzugriff (PDF)

1550P Evaluating the novel combination of pressurized intraperitoneal aerosol chemotherapy-oxaliplatin (PIPAC-OX) as an immunomodulator in combination with systemic nivolumab for gastric cancer peritoneal metastases

Annals of oncology, 2023-10, Vol.34, p.S869-S869

2023

Volltextzugriff (PDF)

472P - A phase I study of varlitinib (VAR; ASLAN001) an oral pan-HER tyrosine kinase inhibitor (TKI) combined with mFOLFIRI chemotherapy in advanced solid tumours

Annals of oncology, 2019-10, Vol.30, p.v178-v178

2019

Volltextzugriff (PDF)

A phase I study of varlitinib (VAR; ASLAN001) an oral pan-HER tyrosine kinase inhibitor (TKI) combined with mFOLFIRI chemotherapy in advanced solid tumours

Annals of oncology, 2019-10, Vol.30, p.v178

2019

Volltextzugriff (PDF)

462P - A phase I open-label, non-randomized study of recombinant super-compound interferon (rSIFN-co) in patients with advanced solid tumours

Annals of oncology, 2019-10, Vol.30, p.v173-v173

2019

Volltextzugriff (PDF)

A phase I open-label, non-randomized study of recombinant super-compound interferon (rSIFN-co) in patients with advanced solid tumours

Annals of oncology, 2019-10, Vol.30, p.v173

2019

Volltextzugriff (PDF)

Chemoradiation-Induced Intratumoral Immune Microenvironment Changes In Esophageal Cancer

International journal of radiation oncology, biology, physics, 2020-11, Vol.108 (3), p.e604-e604

2020

Volltextzugriff (PDF)

PO-1034: Chemoradiation-induced intratumoral immune microenvironment changes in oesophageal cancer

Radiotherapy and oncology, 2020-11, Vol.152, p.S550-S551

2020

Volltextzugriff (PDF)

1189PD - Determinants of response of HER2+ gastric cancer (GC) vs gastroesophageal junction adenocarcinoma (GEJ) to margetuximab (M) plus pembrolizumab (P) post trastuzumab (T)

Annals of oncology, 2019-10, Vol.30, p.v485-v485

2019

Volltextzugriff (PDF)

123P - Evaluation of tumour microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA)

Annals of oncology, 2019-10, Vol.30, p.v38-v39

2019

Volltextzugriff (PDF)

Determinants of response of HER2+ gastric cancer (GC) vs gastroesophageal junction adenocarcinoma (GEJ) to margetuximab (M) plus pembrolizumab (P) post trastuzumab (T)

Annals of oncology, 2019-10, Vol.30, p.v485

2019

Volltextzugriff (PDF)

Evaluation of tumour microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA)

Annals of oncology, 2019-10, Vol.30, p.v38-v39

2019

Volltextzugriff (PDF)

1188PD - Margetuximab (M) + pembrolizumab (P) for treatment of patients (pts) with HER2+ gastroesophageal adenocarcinoma (GEA) post-trastuzumab (T): Survival analysis

Annals of oncology, 2019-10, Vol.30, p.v484-v485

2019

Volltextzugriff (PDF)

Margetuximab (M) + pembrolizumab (P) for treatment of patients (pts) with HER2+ gastroesophageal adenocarcinoma (GEA) post-trastuzumab (T): Survival analysis

Annals of oncology, 2019-10, Vol.30, p.v484-v485

2019

Volltextzugriff (PDF)

85O Low-pass whole genome sequencing (lpWGS) to quantify circulating tumor DNA (ctDNA) burden as a pharmacodynamic response biomarker in patients on early phase trials

ESMO open, 2024-02, Vol.9, p.102311, Article 102311

2024

Volltextzugriff (PDF)

Phase I PIANO trial—PIPAC-oxaliplatin and systemic nivolumab combination for gastric cancer peritoneal metastases: clinical and translational outcomes

ESMO open, 2024-09, Vol.9 (9), p.103681, Article 103681

2024

Volltextzugriff (PDF)

Trials without borders—decentralized trials and ensuring access to novel cancer therapies during a global pandemic

ESMO open, 2022-08, Vol.7 (4), p.100537-100537, Article 100537

2022

Volltextzugriff (PDF)

PH-0169: Dosimetric comparison of IMRT and IMPT in the treatment of recurrent nasopharyngeal carcinoma

Radiotherapy and oncology, 2020-11, Vol.152, p.S82-S82

2020

Volltextzugriff (PDF)

Comparison of Planning Quality and Efficiency Between Conventional and Knowledge-Based Algorithms in Nasopharyngeal Cancer Patients Using Intensity Modulated Radiation Therapy

International journal of radiation oncology, biology, physics, 2015-11, Vol.93 (3), p.E320-E320

2015

Volltextzugriff (PDF)

The Efficiency of Adaptive Intensity Modulated Radiation Therapy Treatment (IMRT) Planning in Nasopharyngeal Carcinoma (NPC) Using Deformable Auto-Segmentation (AS) and Knowledge-Based Planning (KBP)

International journal of radiation oncology, biology, physics, 2018-11, Vol.102 (3), p.e536-e537

2018

Volltextzugriff (PDF)

Analysis of Radiotherapy to Recurrent Nasopharyngeal Carcinoma (NPC) in Hong Kong

International journal of radiation oncology, biology, physics, 2019-09, Vol.105 (1), p.E389-E390

2019

Volltextzugriff (PDF)

2373

International journal of radiation oncology, biology, physics, 2006-11, Vol.66 (3), p.S417-S418

2006

Volltextzugriff (PDF)

2373: Fitting of Biological Parameters for Tumor Control Probability of Nasopharyngeal Carcinoma

International journal of radiation oncology, biology, physics, 2006, Vol.66 (3), p.S417-S418

2006

Volltextzugriff (PDF)

1 – 23 von 23

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(22)

Publikationsform

Artikel
(23)

Sprache

Englisch
(23)

Erscheinungsjahr

n.n

Thema

Correspondence
(1)
Gastric Cancer
(1)
Hematology, Oncology And Palliative Medicine
(1)
Immunotherapy
(1)
Intraperitoneal
(1)
Locoregional Therapy
(1)
Niche
(1)
Original Research
(1)
Peritoneal Metastases
(1)
Peritoneum
(1)
Pipac
(1)
Radiology
(1)
Tumor Microenvironment
(1)

8 weitere anzeigen...

Weniger anzeigen...

Kollektion

Zeitschrift / Serie

Annals Of Oncology
(12)
International Journal Of Radiation Oncology, Biology, Physics
(6)
Esmo Open
(3)
Radiotherapy And Oncology
(2)

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

653P A phase I dose escalation study of EBC-129, a first-in class, anti N-glycosylated CEACAM5 & CEACAM6 antibody-drug conjugate (ADC) in patients with solid tumors

1550P Evaluating the novel combination of pressurized intraperitoneal aerosol chemotherapy-oxaliplatin (PIPAC-OX) as an immunomodulator in combination with systemic nivolumab for gastric cancer peritoneal metastases

472P - A phase I study of varlitinib (VAR; ASLAN001) an oral pan-HER tyrosine kinase inhibitor (TKI) combined with mFOLFIRI chemotherapy in advanced solid tumours

A phase I study of varlitinib (VAR; ASLAN001) an oral pan-HER tyrosine kinase inhibitor (TKI) combined with mFOLFIRI chemotherapy in advanced solid tumours

462P - A phase I open-label, non-randomized study of recombinant super-compound interferon (rSIFN-co) in patients with advanced solid tumours

A phase I open-label, non-randomized study of recombinant super-compound interferon (rSIFN-co) in patients with advanced solid tumours

Chemoradiation-Induced Intratumoral Immune Microenvironment Changes In Esophageal Cancer

PO-1034: Chemoradiation-induced intratumoral immune microenvironment changes in oesophageal cancer

1189PD - Determinants of response of HER2+ gastric cancer (GC) vs gastroesophageal junction adenocarcinoma (GEJ) to margetuximab (M) plus pembrolizumab (P) post trastuzumab (T)

123P - Evaluation of tumour microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA)

Determinants of response of HER2+ gastric cancer (GC) vs gastroesophageal junction adenocarcinoma (GEJ) to margetuximab (M) plus pembrolizumab (P) post trastuzumab (T)

Evaluation of tumour microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA)

1188PD - Margetuximab (M) + pembrolizumab (P) for treatment of patients (pts) with HER2+ gastroesophageal adenocarcinoma (GEA) post-trastuzumab (T): Survival analysis

Margetuximab (M) + pembrolizumab (P) for treatment of patients (pts) with HER2+ gastroesophageal adenocarcinoma (GEA) post-trastuzumab (T): Survival analysis

85O Low-pass whole genome sequencing (lpWGS) to quantify circulating tumor DNA (ctDNA) burden as a pharmacodynamic response biomarker in patients on early phase trials

Phase I PIANO trial—PIPAC-oxaliplatin and systemic nivolumab combination for gastric cancer peritoneal metastases: clinical and translational outcomes

Trials without borders—decentralized trials and ensuring access to novel cancer therapies during a global pandemic

PH-0169: Dosimetric comparison of IMRT and IMPT in the treatment of recurrent nasopharyngeal carcinoma

Comparison of Planning Quality and Efficiency Between Conventional and Knowledge-Based Algorithms in Nasopharyngeal Cancer Patients Using Intensity Modulated Radiation Therapy

The Efficiency of Adaptive Intensity Modulated Radiation Therapy Treatment (IMRT) Planning in Nasopharyngeal Carcinoma (NPC) Using Deformable Auto-Segmentation (AS) and Knowledge-Based Planning (KBP)

Analysis of Radiotherapy to Recurrent Nasopharyngeal Carcinoma (NPC) in Hong Kong

2373

2373: Fitting of Biological Parameters for Tumor Control Probability of Nasopharyngeal Carcinoma

Suchergebnisse filtern